Background:The glycoprotein known as anti-Müllerian hormone (AMH) belongs to the family of transforming growth factor beta (TGF-β).Serum AMH levels are sensitive and specific for ovarian responses during gonadotropin stimulation, according to recent research, which makes it ideal for in vitro conception.AMH may be used to diagnose and treat a number of ovarian diseases, such as polycystic ovary syndrome (PCOS), granulosa cell cancers, and premature ovarian aging, in addition to evaluating ovarian reserve.Objective: This review article is intended to provide in-depth knowledge about the role of AMH in female fertility.Methods: This topic was derived from articles that were searched and screened using PubMed, Google Scholar, and Sci-Hub.Results: Compared to more traditional hormonal indicators of ovarian reserve, such as follicle-stimulating hormone (FSH), estradiol (E2), or inhibin B, serum AMH testing has a number of benefits.Despite not being able to predict conception or oocyte quality, it has been acknowledged for a number of years as the greatest hormonal indication of ovarian reserve.However, consistency of AMH measurement is necessary to maximize clinical usage.The number of tests for measuring AMH has grown in recent years.There are variations among tests, though.Therefore, in order to establish independent test cutoff values, a worldwide standard for AMH is desperately needed.Conclusion: It may be helpful to test serum AMH in order to predict the ovarian response to assisted reproductive technology (ART) stimulation, the onset of menopause, and iatrogenic amenorrhea.
No takes yet. Share an insight, caveat, or question.
Edelweishia et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: